

United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	F	ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/939,709	939,709 08/28/2001		Roland E. Baron	044574-5045-US	2739
9629	7590	11/21/2002		1	•
		& BOCKIUS LLP	EXAMINER		
1111 PENN WASHING		IA AVENUE NW 20004		WOITACH,	JOSEPH T
				ART UNIT	PAPER NUMBER
				1632	1.
				DATE MAILED: 11/21/2002	

Please find below and/or attached an Office communication concerning this application or proceeding.



Applicant(s)

Application No. 09/939,709

Baron et al.

Office Action Summary Examiner

Joseph Woitach

Art Unit 1632

The MAILING DATE of this communication appears on the cover sheet with the correspondence address						
Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.						
If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
Status						
1) X Responsive to communication(s) filed on <u>Feb 1, 20</u>	002					
2a) ☐ This action is FINAL . 2b) ☒ This ac	tion is non-final.					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11; 453 O.G. 213.						
Disposition of Claims						
4) 💢 Claim(s) <u>1-30</u>	is/are pending in the application.					
4a) Of the above, claim(s)	is/are withdrawn from consideration.					
5)	is/are allowed.					
6)	is/are rejected.					
7) Claim(s)	is/are objected to.					
8) 💢 Claims <u>1-30</u>	are subject to restriction and/or election requirement.					
Application Papers						
9) \square The specification is objected to by the Examiner.						
10) The drawing(s) filed on is/ar	e a) \square accepted or b) \square objected to by the Examiner.					
Applicant may not request that any objection to the	drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
11) The proposed drawing correction filed on	is: a) \square approved b) \square disapproved by the Examiner.					
If approved, corrected drawings are required in reply	to this Office action.					
12) The oath or declaration is objected to by the Exam	niner.					
Priority under 35 U.S.C. §§ 119 and 120						
13) Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a) \square All b) \square Some* c) \square None of:						
1. Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).						
*See the attached detailed Office action for a list of the certified copies not received.						
14) X Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).						
a) U The translation of the foreign language provisional application has been received.						
15) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.						
Attachment(s) 1) Notice of References Cited (PTO-892)	4) Interview Summary (PTO-413) Paper No(s).					
Notice of Dreftsperson's Patent Drawing Review (PTO-948)	5) Notice of Informal Patent Application (PTO-152)					
3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)						
	·· 🗀					

Art Unit: 1632

DETAILED ACTION

This application filed August 28, 2001 claims benefit to provisional application 60/228,450, filed August 29, 2000.

Applicants' amendment filed February 1, 2002, paper number 8, has been received and entered. The specification has been amended. The application is in sequence compliance.

Election/Restriction

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-15, 21 and 22, drawn to a method of identifying an agent that modulates bone formation or adipogenesis comprising administering an agent and monitoring ΔFosB, classified in class 435, subclass 6.
- II. Claims 16, 17, 19 and 20, drawn to method of inducing bone formation or adipogenesis by inducing ΔFosB expression, classified in various classes depending on agent delivered for example class 514, subclass 1 (undefined organic agent); class 514, subclass 2 (administering antibody) or class 514, subclass 44 (administering polynucleotide).
- III. Claim 18, drawn to method of treating osteosclerosis by <u>inhibiting</u> ΔFosB
 expression, classified in various classes depending on agent delivered for example



Application/Control Number: 09/939,709

Art Unit: 1632

class 514, subclass 1 (undefined organic agent); class 514, subclass 2 (administering antibody) or class 514, subclass 44 (administering polynucleotide).

- IV. Claims 23 and 24, drawn to a method of identifying genes which are modulated
 by ΔFosB, classified in class 536, subclass 23.1.
- V. Claims 25-30, drawn to a method of identifying genes which modulate Δ FosB expression, classified in class 536, subclass 23.1.

The inventions are distinct, each from the other because of the following reasons:

Inventions I and II-V are related as method making a product and a process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product. In the instant case the methods are different and distinct requiring different method steps and materials to practice. Further, the potential products generated from the method of Group I can be used in a variety of methods as set forth in Groups II-V. Additionally, the agents obtained from the method of Group I can be used to analyze other physiological effects of the agent or the effect on other genes other than DFosB.

Inventions II-V are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different

Application/Control Number: 09/939,709

Art Unit: 1632

inventions are drawn to separate and distinct methods requiring different materials and method steps to practice. The methods of Group II and IV require inducing expression of Δ FosB which may require different materials to affect the first step, and additionally, they differ in the second step of what is affected wherein group II affects the physiology of a whole animal and group IV affects only gene expression in a cell with no physiological consequence, each a different method step requiring different materials to practice. The method of Group III encompasses a unique first and second step requiring first the opposite effect of Groups II and IV by inhibiting Δ FosB expression and second appraises a different physiological effect than Group II. Group V is unrelated to any of II-IV because it administers unknown genes and simply monitors Δ FosB expression with no consequence of Δ FosB expression. None of the other methods require administering test genes or monitoring Δ FosB expression, and the final step of Group V results in a materially different outcome than the other methods encompassed by Groups II-IV.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, divergent subject matter and separate search requirement, restriction for examination purposes as indicated is proper.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any

Application/Control Number: 09/939,709

Art Unit: 1632

amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the

Page 5

fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner

should be directed to Joseph Woitach whose telephone number is (703)305-3732.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Deborah Reynolds, can be reached at (703)305-4051.

Any inquiry of a general nature or relating to the status of this application should be

directed to the Group analyst Dianiece Jacobs whose telephone number is (703) 308-2141.

Papers related to this application may be submitted by facsimile transmission. Papers

should be faxed via the PTO Fax Center located in Crystal Mall 1. The faxing of such papers

must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15,

1989). The CM1 Fax Center numbers are (703)308-4242 and (703)305-3014.

Joseph T. Woitach